Sotabase

Career

· Co-Founder and CTO, Orion2025–
· CEO, Jordan.ai2022–2024
· Lead Engineer and COO, Kargo2020–2022
· Software Engineer, Facebook2019–2019
· Teaching Assistant - CS 106B: Programming Abstractions, Stanford University2019–
· Section Leader - Computer Science, Stanford University2018–2019
· Graduate Student, Stanford University2017–2019
· Senior VP, Sales, AST Defeasance

Publications (185)

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
Nature Medicine · 2001
522
cited
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer Research · 2006
487
cited
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Molecular Therapy · 2004
445
cited
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.
Journal of Clinical Oncology · 2003
401
cited
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of Clinical Oncology · 2005
392
cited
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Journal of Clinical Oncology · 2009
356
cited
Seeding of intravascular stents with genetically engineered endothelial cells.
Circulation · 1989
335
cited
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood · 2007
280
cited
Site-directed neovessel formation in vivo.
Science · 1988
276
cited
Presence of transforming growth factors in human breast cancer cells.
Cancer Research · 1984
242
cited
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research · 2009
241
cited
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Blood · 2003
222
cited
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Journal of Clinical Oncology · 2020
203
cited
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Clinical Cancer Research · 2007
202
cited
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Journal of Clinical Oncology · 2010
194
cited
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias
Clinical Cancer Research · 2004
178
cited
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
Journal of Clinical Oncology · 2006
176
cited
Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer
Journal of Experimental Medicine · 1987
169
cited
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Journal of the National Cancer Institute · 2020
169
cited
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Journal of Clinical Endocrinology and Metabolism · 2009
165
cited
Sotabase
Jonathan Henry Zwiebel | Researcher Profile | Sotabase | Sotabase